Takeda Pharmaceutical Co. $TAK Stock Position Lowered by Ritholtz Wealth Management

Ritholtz Wealth Management decreased its stake in Takeda Pharmaceutical Co. (NYSE:TAK) by 59.7% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 23,852 shares of the company’s stock after selling 35,307 shares during the quarter. Ritholtz Wealth Management’s holdings in Takeda Pharmaceutical were worth $372,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in TAK. UBS Group AG lifted its position in Takeda Pharmaceutical by 46.4% in the 3rd quarter. UBS Group AG now owns 5,893,969 shares of the company’s stock worth $86,288,000 after buying an additional 1,869,323 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its position in Takeda Pharmaceutical by 132.1% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,828,778 shares of the company’s stock worth $41,413,000 after buying an additional 1,610,088 shares in the last quarter. Qube Research & Technologies Ltd lifted its position in Takeda Pharmaceutical by 407.9% in the 3rd quarter. Qube Research & Technologies Ltd now owns 1,775,845 shares of the company’s stock worth $25,998,000 after buying an additional 1,426,184 shares in the last quarter. Bank of America Corp DE lifted its position in Takeda Pharmaceutical by 225.8% in the 2nd quarter. Bank of America Corp DE now owns 1,037,163 shares of the company’s stock worth $16,035,000 after buying an additional 718,805 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its position in Takeda Pharmaceutical by 15.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company’s stock worth $79,120,000 after buying an additional 692,404 shares in the last quarter. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on TAK shares. Zacks Research upgraded shares of Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 3rd. Morgan Stanley started coverage on shares of Takeda Pharmaceutical in a research report on Tuesday, January 13th. They issued an “overweight” rating for the company. Sanford C. Bernstein upgraded shares of Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a research report on Wednesday, April 8th. Wall Street Zen upgraded shares of Takeda Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, April 11th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Takeda Pharmaceutical in a research report on Monday, December 29th. Two analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, Takeda Pharmaceutical presently has an average rating of “Moderate Buy”.

Takeda Pharmaceutical Stock Down 0.4%

Takeda Pharmaceutical stock opened at $17.79 on Friday. The company has a market capitalization of $56.60 billion, a P/E ratio of 74.11 and a beta of -0.01. The firm’s fifty day simple moving average is $18.23 and its 200-day simple moving average is $16.07. The company has a current ratio of 1.19, a quick ratio of 0.65 and a debt-to-equity ratio of 0.56. Takeda Pharmaceutical Co. has a 1-year low of $12.99 and a 1-year high of $18.90.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings results on Friday, January 30th. The company reported $0.48 earnings per share for the quarter, missing analysts’ consensus estimates of $0.55 by ($0.07). The business had revenue of $7.60 billion for the quarter, compared to the consensus estimate of $7.81 billion. Takeda Pharmaceutical had a net margin of 2.58% and a return on equity of 10.60%. Takeda Pharmaceutical has set its FY 2025 guidance at 3.160-3.160 EPS. Sell-side analysts forecast that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current fiscal year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.